comparemela.com

Latest Breaking News On - Katie mcmanus - Page 6 : comparemela.com

Trevi Therapeutics to Participate in Upcoming May Investor Events

/PRNewswire/ Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral.

United statesFarrell simonRosalia scampoliLisa delfiniKatie mcmanusPeter dicpinigaitisDivision of critical care medicinePrnewswire trevi therapeutics incMontefiore medical centerAmerican thoracic societyTrevi therapeutics incMontefiore cough centerAlbert einstein collegeVirtual conferenceThoracic societyInnovation summit

Trevi Therapeutics to Participate in the 22nd Annual Needham Virtual Healthcare Conference

Fireside chat will be held on Monday, April 17, 2023, at 11:00 a.m. ET NEW HAVEN, Conn., April 11, 2023 /PRNewswire/ Trevi Therapeutics, Inc. , a clinical-stage biopharmaceutical company. | April 11, 2023

United statesDavid clarkRosalia scampoliLisa delfiniKatie mcmanusPrnewswire trevi therapeutics incTrevi therapeutics incCompany on twitterJennifer goodChief executive officerChief financial officerChief medical officerAnnual needham virtual healthcare conferenceTrevi therapeuticsNc stock exchangePress release

Trevi Therapeutics Announces Fourth Quarter and Year End 2022 Financial Results and Provides Business Update

/PRNewswire/ Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral.

United statesUnited kingdomRosalia scampoliKatie mcmanusDavid clarkTrevi haduvioPrnewswire trevi therapeutics incCompany on twitterDrug administrationDrug enforcement agencyExchange commissionBritish thoracic society winter meetingTrevi therapeutics incJennifer goodYear end businessPbritish thoracic society

Trevi Therapeutics Announces Notice of Allowance for U S Patent Application Covering Use of Haduvio™ (nalbuphine ER) for the Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis

/PRNewswire/ Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral.

United statesRosalia scampoliKatie mcmanusTrevi haduvioExchange commissionTrademark officePrnewswire trevi therapeutics incTrevi therapeutics incUnited states patentOrange book listableJennifer goodChronic coughIdiopathic pulmonaryTrevi therapeuticsPrivate securities litigation reform act

Trevi Therapeutics Announces Notice of Allowance for U S Patent Application Covering Use of Haduvio™ (nalbuphine ER) for the Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis

NEW HAVEN, Conn., March 8, 2023 /PRNewswire/ Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in adults w.

United statesRosalia scampoliKatie mcmanusTrevi haduvioExchange commissionTrademark officePrnewswire trevi therapeutics incTrevi therapeutics incUnited states patentOrange book listableJennifer goodChronic coughIdiopathic pulmonaryTrevi therapeuticsPrivate securities litigation reform act

vimarsana © 2020. All Rights Reserved.